Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209–16.

PubMed  Article  PubMed Central  Google Scholar 

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–38.

PubMed  PubMed Central  Article  Google Scholar 

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Riddell Jt AKR, Mayer KHHIV. Preexposure prophylaxis: a review. Jama. 2018;319(12):1261–8.

Article  Google Scholar 

World Health Organization. Global health sector strategy on HIV, 2016-2021. Geneva: WHO; 2016.

Google Scholar 

Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56.

PubMed  Article  PubMed Central  Google Scholar 

Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.

PubMed  Article  PubMed Central  Google Scholar 

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infections. Recommendation for a public health approach Geneva 2016 2016.

Google Scholar 

Dimitrov DT, Boily MC, Hallett TB, Albert J, Boucher C, Mellors JW, et al. How much do we know about drug resistance due to prep use? analysis of experts’ opinion and its influence on the projected public health impact. PLoS One. 2016;11(7):e0158620.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6(1):22–33.

PubMed  PubMed Central  Google Scholar 

van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis. 2010;23(6):621–7.

PubMed  Article  CAS  PubMed Central  Google Scholar 

van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. Aids. 2013;27(18):2943–51.

PubMed  Article  CAS  PubMed Central  Google Scholar 

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.

CAS  PubMed  Article  Google Scholar 

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

PubMed  Article  Google Scholar 

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.

CAS  PubMed  Article  Google Scholar 

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.

PubMed  PubMed Central  Article  Google Scholar 

•• Mayer KH, Molina J-M, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide <em>vs</em> emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54. Recent randomized controlled trial showing that PrEP as TAF/FTC is superior to PrEP as TDF/FTC.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother. 2006;50(12):4087–95.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. Aids 2015;29(3):331–7.

Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med. 2017;376(5):501–2.

PubMed  Article  PubMed Central  Google Scholar 

• Thaden JT, Gandhi M, Okochi H, Hurt CB, McKellar MS. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination. Aids. 2018;32(9):F1–f4. One the three case reports describing PrEP failure due to transmission of HIV resistant to TDF and FTC.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, et al. Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis. J Acquir Immune Defic Syndr. 2017;76(4):e104–e6.

PubMed  PubMed Central  Article  Google Scholar 

Kuritzkes DR. Preventing and managing resistance in the clinical setting. JAcquirImmuneDeficSyndr. 2003;34(Suppl 2):S103–S10.

Google Scholar 

Bennett B, Branson B, Delaney K, Owen M, Pentella M, Werner B. HIV testing algorithms: a status report. Silver Spring: The Association of Public Health Laboratories; 2009.

Google Scholar 

Cuevas JM, Geller R, Garijo R, Lopez-Aldeguer J, Sanjuan R. Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol. 2015;13(9):e1002251.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the k65r resistance mutation in HIV-1 subtype C. J Infect Dis. 2009;200(8):1202–6.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20(9):F9–13.

CAS  PubMed  Article  PubMed Central  Google Scholar 

• Misra K, Huang J, Daskalakis DC, Udeagu CC. Impact of PREP on drug resistance and acute HIV infection, NEW YORK CITY, 2015-2017. Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7 2019; Seattle; 2019. p. Abstract 107. Study only published as an abstract showing that about 25% of patients who used PrEP before diagnosis are infected with a virus resistant to emtricitabibe

Google Scholar 

•• Tittle V, Boffito M, McOwan A, Whitlock G. Antiretroviral resistance and management after pre-exposure prophylaxis. Lancet HIV. 2020;7(2):e84. Summary of patients who used PrEP before diagnosis and in whom about 25% had a virus resistant to emtricitabine. The study includes an overview of the antiretroviral drug treatment given to the patients.

PubMed  Article  PubMed Central  Google Scholar 

Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra4.

PubMed  Article  CAS  PubMed Central  Google Scholar 

• Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2020;324(16):1651–69. International HIV treatment guideline that includes expert opinion and anecdotal evidence of treatment of patients in whom drug resistance due to PrEP can be found.

CAS  PubMed  Article  PubMed Central  Google Scholar 

Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011;203(8):1174–81.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, et al. HIV-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy. J Infect Dis. 2018;218(5):688–97.

CAS  PubMed  Article  Google Scholar 

Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). JInfectDis. 1995;171(6):1411–9.

CAS  Article  Google Scholar 

Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis. 1997;176(2):398–405.

CAS